The Role of Rosa Canina in Modulating NF-Κb and MAPK Signaling Pathways: A Key to Anti-Inflammatory Therapy
DOI:
https://doi.org/10.22270/ajprd.v13i1.1516Abstract
Rosa canina L., which is more commonly known as rosehip, has become a plant of great scientific interest due to its nutritional, cosmetic, and therapeutic applications. This review study highlights the fact that the high levels of vitamins, carotenoids, tocopherol, and phenolic acid in this substance are responsible for its anticarcinogenic, hepatoprotective, antioxidant, and anti-inflammatory properties. The German Commission E published a negative monograph on rose hip, rose hip and seed, and rose hip seed due to insufficient evidence of their effects and usefulness. As a result, a literature review was conducted to outline the pharmacological and clinical effects of Rosa canina L. in order to re-evaluate its usefulness in traditional medicine. Several rose hip and rose hip and seed formulations have been demonstrated to offer antioxidant and anti-inflammatory effects. Such action mechanisms involve lipophilic components. Litozin, a proprietary powder made from rose hips and seeds, has been shown to be beneficial in treating patients with osteoarthritis, rheumatoid arthritis, and low back pain in several exploratory investigations. In addition to vitamin C, a number of the components found in rose hips possess strong antioxidant and radical scavenging activities. The pharmacological and clinical effects that were found can be explained by a number of different components, including as phenolics, terpenoids, galactolipids, carotenoids, fruit acids, and fatty oils. In addition, anti-inflammatory effects include lowering the levels of pro-inflammatory cytokines and chemokines, NF-kB signalling, pro-inflammatory enzymes (COX1/2, 5-LOX, and iNOS), C-reactive protein levels, PMN chemotaxis and chemoluminescence, and pro-inflammatory metalloproteases.
Downloads
References
Zhou Y, Hong Y, Huang H. Triptolide attenuates inflammatory response in membranous glomerulo-nephritis rat via downregulation of NF-κB signaling pathway. Kidney and Blood Pressure Research. 2016 Dec 23;41(6):901-10.
Medzhitov R. Inflammation 2010: new adventures of an old flame. Cell. 2010 Mar 19;140(6):771-6.
Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X, Zhao L. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017 Dec 14;9(6):7204.
Chertov O, Yang D, Howard OM, Oppenheim JJ. Leukocyte granule proteins mobilize innate host defenses and adaptive immune responses. Immunological reviews. 2000 Oct 1;177:68-78.
Jabbour HN, Sales KJ, Catalano RD, Norman JE. Inflammatory pathways in female reproductive health and disease. Reproduction. 2009 Dec 1;138(6):903.
Guo Q, Jin Y, Chen X, Ye X, Shen X, Lin M, Zeng C, Zhou T, Zhang J. NF-κB in biology and targeted therapy: new insights and translational implications. Signal Transduction and Targeted Therapy. 2024 Mar 4;9(1):53.
Yu H, Lin L, Zhang Z, Zhang H, Hu H. Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study. Signal transduction and targeted therapy. 2020 Sep 21;5(1):209.
Shih RH, Wang CY, Yang CM. NF-kappaB signaling pathways in neurological inflammation: a mini review. Frontiers in molecular neuroscience. 2015 Dec 18;8:77.
Xiao K, Liu C, Tu Z, Xu Q, Chen S, Zhang Y, Wang X, Zhang J, Hu CA, Liu Y. Activation of the NF‐κB and MAPK Signaling Pathways Contributes to the Inflammatory Responses, but Not Cell Injury, in IPEC‐1 Cells Challenged with Hydrogen Peroxide. Oxidative Medicine and Cellular Longevity. 2020;2020(1):5803639.
Ebrahimi N, Abdulwahid AH, Mansouri A, Karimi N, Bostani RJ, Beiranvand S, Adelian S, Khorram R, Vafadar R, Hamblin MR, Aref AR. Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy. Cellular and Molecular Life Sciences. 2024 Dec;81(1):106.
Awuchi CG, Amagwula IO, Priya P, Kumar R, Yezdani U, Khan MG. Aflatoxins in foods and feeds: A review on health implications, detection, and control. Bull. Environ. Pharmacol. Life Sci. 2020 Aug 9;9:149-55.
Saha P, Kumar A, Bhanja J, Shaik R, Kawale AL, Kumar R. A review of immune blockade safety and antitumor activity of dostarlimab therapy in endometrial cancer. International Journal for Research in Applied Sciences and Biotechnology. 2022 Jun 22;9(3):201-9.
Chen L, Wang J, Ren Y, Ma Y, Liu J, Jiang H, Liu C. Artesunate improves glucose and lipid metabolism in db/db mice by regulating the metabolic profile and the MAPK/PI3K/Akt signalling pathway. Phytomedicine. 2024 Apr 1;126:155382.
Saleem S. Targeting MAPK signaling: A promising approach for treating inflammatory lung disease. Pathology-Research and Practice. 2024 Jan 11:155122.
Shi A, Liu L, Li S, Qi B. Natural products targeting the MAPK-signaling pathway in cancer: overview. Journal of Cancer Research and Clinical Oncology. 2024 Jan;150(1):6.
Roman I, Stănilă A, Stănilă S. Bioactive compounds and antioxidant activity of Rosa canina L. biotypes from spontaneous flora of Transylvania. Chemistry central journal. 2013 Dec;7:1-0.
Wanes D, Jabri MA, Tounsi H, Rtibi K, Zouari N, Hajji N, Jridi M, Abdellaoui A, Sebai H. Chemical characterization of bioactive components of Rosa canina extract and its protective effect on dextran sulfate sodium-induced intestinal bowel disease in a mouse model. Journal of medicinal food. 2020 Oct 1;23(10):1109-19.
Negrean OR, Farcas AC, Nemes SA, Cic DE, Socaci SA. Recent advances and insights into the bioactive properties and applications of Rosa canina L. and its by-products. Heliyon. 2024 May 7.
Lawrence T. The nuclear factor NF-κB pathway in inflammation. Cold Spring Harbor perspectives in biology. 2009 Dec 1;1(6):a001651.
Shih RH, Wang CY, Yang CM. NF-kappaB signaling pathways in neurological inflammation: a mini review. Frontiers in molecular neuroscience. 2015 Dec 18;8:77.
Oeckinghaus A, Ghosh S. The NF-κB family of transcription factors and its regulation. Cold Spring Harbor perspectives in biology. 2009 Oct 1;1(4):a000034.
Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal transduction and targeted therapy. 2017 Jul 14;2(1):1-9.
Zhang T, Ma C, Zhang Z, Zhang H, Hu H. NF‐κB signaling in inflammation and cancer. MedComm. 2021 Dec;2(4):618-53.
Wang S, Liu Z, Wang L, Zhang X. NF-κB signaling pathway, inflammation and colorectal cancer. Cellular & molecular immunology. 2009 Oct;6(5):327-34.
Salminen A, Hyttinen JM, Kaarniranta K. AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan. Journal of molecular medicine. 2011 Jul;89:667-76.
Saha P, Kumar R, Nyarko RO, Kahwa I, Owusu P. Herbal Secondary Metabolite For Gastro-Protective Ulcer Activity With Api Structures.
Roberti A, Chaffey LE, Greaves DR. NF-κB signaling and inflammation—Drug repurposing to treat inflammatory disorders?. Biology. 2022 Feb 26;11(3):372.
O'Dea E, Hoffmann A. NF‐κB signaling. Wiley Interdisciplinary Reviews: Systems Biology and Medicine. 2009 Jul;1(1):107-15.
Napetschnig J, Wu H. Molecular basis of NF-κB signaling. Annual review of biophysics. 2013 May 6;42(1):443-68.
Bhat AA, Afzal O, Agrawal N, Thapa R, Almalki WH, Kazmi I, Alzarea SI, Altamimi AS, Kukreti N, Chakraborty A, Singh SK. A comprehensive review on the emerging role of long non-coding RNAs in the regulation of NF-κB signaling in inflammatory lung diseases. International journal of biological macromolecules. 2023 Sep 19:126951.
Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2010 Apr 1;1802(4):396-405.
Yue J, López JM. Understanding MAPK signaling pathways in apoptosis. International journal of molecular sciences. 2020 Mar 28;21(7):2346.
Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell research. 2002 Mar;12(1):9-18.
Geest CR, Coffer PJ. MAPK signaling pathways in the regulation of hematopoiesis. Journal of leukocyte biology. 2009 Aug;86(2):237-50.
Keren A, Tamir Y, Bengal E. The p38 MAPK signaling pathway: a major regulator of skeletal muscle development. Molecular and cellular endocrinology. 2006 Jun 27;252(1-2):224-30.
Braicu C, Buse M, Busuioc C, Drula R, Gulei D, Raduly L, Rusu A, Irimie A, Atanasov AG, Slaby O, Ionescu C. A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers. 2019 Oct 22;11(10):1618.
Bahar ME, Kim HJ, Kim DR. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal transduction and targeted therapy. 2023 Dec 18;8(1):455.
Cheng Y, Chen J, Shi Y, Fang X, Tang Z. MAPK signaling pathway in oral squamous cell carcinoma: biological function and targeted therapy. Cancers. 2022 Sep 23;14(19):4625.
García-Hernández L, García-Ortega MB, Ruiz-Alcalá G, Carrillo E, Marchal JA, García MÁ. The p38 MAPK components and modulators as biomarkers and molecular targets in cancer. International journal of molecular sciences. 2021 Dec 29;23(1):370.
Yuan W, Shi Y, Dai S, Deng M, Zhu K, Xu Y, Chen Z, Xu Z, Zhang T, Liang S. The role of MAPK pathway in gastric cancer: unveiling molecular crosstalk and therapeutic prospects. Journal of Translational Medicine. 2024 Dec 24;22(1):1142.
Wei J, Liu R, Hu X, Liang T, Zhou Z, Huang Z. MAPK signaling pathway-targeted marine compounds in cancer therapy. Journal of Cancer Research and Clinical Oncology. 2021 Jan;147:3-22.
Arafa ES, Refaey MS, Abd El-Ghafar OA, Hassanein EH, Sayed AM. The promising therapeutic potentials of ginsenosides mediated through p38 MAPK signaling inhibition. Heliyon. 2021 Nov 1;7(11).
Yan Y, Dai T, Guo M, Zhao X, Chen C, Zhou Y, Qin M, Xu L, Zhao J. A review of non-classical MAPK family member, MAPK4: A pivotal player in cancer development and therapeutic intervention. International Journal of Biological Macromolecules. 2024 May 25:132686.
Shi A, Liu L, Li S, Qi B. Natural products targeting the MAPK-signaling pathway in cancer: overview. Journal of Cancer Research and Clinical Oncology. 2024 Jan;150(1):6.
Chen RE, Thorner J. Function and regulation in MAPK signaling pathways: lessons learned from the yeast Saccharomyces cerevisiae. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2007 Aug 1;1773(8):1311-40.
Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell research. 2002 Mar;12(1):9-18.
Jiménez S, Gascón S, Luquin A, Laguna M, Ancin-Azpilicueta C, Rodríguez-Yoldi MJ. Rosa canina extracts have antiproliferative and antioxidant effects on Caco-2 human colon cancer. PloS one. 2016 Jul 28;11(7):e0159136.
Roman I, Stănilă A, Stănilă S. Bioactive compounds and antioxidant activity of Rosa canina L. biotypes from spontaneous flora of Transylvania. Chemistry central journal. 2013 Dec;7:1-0.
Forouzanfar F, Tabatabaei Z, Emami SA, Ayati Z, Tayarani‐Najaran Z. Protective effects of fruit extract of Rosa canina and quercetin on human umbilical vein endothelial cell injury induced by hydrogen peroxide. Food Science & Nutrition. 2023 Dec;11(12):7618-25.
Khelfi S, Zerizer S, Bensouici C, Tebibel S, Kabouche Z. The antioxidant activity and the protective effect of Rosa canina L. fruit against intestinal inflammation induced by hyperhomocysteinemia in mice. Pharmaceutical Chemistry Journal. 2024 Feb;57(11):1778-88.
Shakibaei M, Allaway D, Nebrich S, Mobasheri A. Botanical extracts from Rosehip (Rosa canina), Willow Bark (Salix alba), and Nettle Leaf (Urtica dioica) suppress IL‐1β‐induced NF‐κB activation in canine articular chondrocytes. Evidence‐Based Complementary and Alternative Medicine. 2012;2012(1):509383.
Lattanzio F, Greco E, Carretta D, Cervellati R, Govoni P, Speroni E. In vivo anti-inflammatory effect of Rosa canina L. extract. Journal of ethnopharmacology. 2011 Sep 1;137(1):880-5.
Winther K, Sophie Vinther Hansen A, Campbell-Tofte J. Bioactive ingredients of rose hips (Rosa canina L) with special reference to antioxidative and anti-inflammatory properties: in vitro studies. Botanics: Targets and Therapy. 2016 Feb 29:11-23.
Published
How to Cite
Issue
Section
Copyright (c) 2025 Sandip Tejpal, Samridhi Dogra, Sachit Sharma
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.